The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
30th june cash balance over 15 million so it seems we are well funded atm . A POSTER said cash burn is approx 780000 a month . BUT dont forget we got a few sales going which helps us . IMO its building up a nice network and in a couple of years we will get our real rewards . I cant see us not getting fda approval . WOULD of thought we would of hit 50p today but it will come very soon . ATB all like this company and happy i invested here
Hi Bradders,
good point, they have tapped the market. My email was pre-covid - I should have mentioned this.
Strange non-reaction in the price (so far).
I thought Dnl had enough cash to last until profitability (21/22) ??
Email from CEO
The interesting points are margin and profitability dates, still some patience required here but seeing the price move recently, I think we may see a steady climb towards these dates.
In answer to your questions (in red):
- do you have cash forecast sales for Alkindi and Chronocort?
The Company does not provide these; however the analysts (Cantor Fitzgerald and Panmure) have sales of Alkindi more than doubling for this financial year (2019/20) and then doubling again the year after (2020/21); Chronocort first sales are expect in the 2021/22 financial year – the market for Chronocort (no. of patients) is approximately 5x as big as for Alkindi with an anticipated similar sales growth trajectory. Hardman research can also be downloaded from our website.
- what sales growth do you expect in the next six to 12 months?
See above
- could you tell me your expected margins on these?
Underlying gross margin is currently around 80% (we are still at relatively low volumes and in the start-up of the marketing phase) we see gross margin growing to >90% in the next 18 months
- do you expect your current cash to last until sales increase? What are your options?
Current cash takes us to Q3,20 – we have guided to closing a deal with a US partner in H1,20 – this could consist of non-dilutive income, including potential for signature fees, milestone payments and development cost funding. Diurnal is also assessing opportunities for both equity and non-equity financing, in order to further extend its cash resources
- when do you forecast Diurnal will break into profit?
If Chronocort is approved in Europe and Alkindi in the US (commercialised by a partner) and no further investment was made in the pipeline, Diurnal could be profitable from 2022/23
if you are permitted to share any other relevant information with me, that would be great
Alkindi approved for review in the US (see enclosed press release) last week, with the earliest approval date set as 29th Sept-20
Hi All,
DNL received a small mention in Shares Magazine (just Israel news), they have supported this company for at least 2 years now and DNL have presented at their events a number of times - I have been holding and building my holding in this company as a result.
As some reassurance to newer investors, this company has delivered on its presentations every time (and they have explained setbacks - e.g. the share price drop some years ago). The CEO has also answered emails (I will try to post).
https://www.sharesmagazine.co.uk/news/market/7033445/Diurnal-adrenal-drug-receives-regulatory-approval-in-Israel